Navigation Links
Manhattan Research Ranks the Top Pharmaceutical Branded Websites by Rx Request Rates
Date:2/4/2008

While Chantix and Cialis Lead, Many Heavily Advertised Brands Lag Behind

NEW YORK, Feb. 4 /PRNewswire/ -- Manhattan Research, a leader in syndicated research and marketing services for the health and pharmaceutical industry, today revealed the top pharmaceutical branded product websites ranked by offline requests by U.S. adult consumers. The product site rankings are based on the comprehensive online consumer research study with 5,112 U.S. adults titled ePharma Consumer(R) v7.0: The Future of Integrated DTC Marketing. In addition to the top product site rankings, the study provides in-depth data on more than 200 leading pharmaceutical product sites including site satisfaction, site search rationales, tools and features desired on product sites, and a wide range of consumer actions taken afterwards.

"Having the most unique visitors is no longer the ultimate goal of a successful pharmaceutical product site," says Mark Bard, president of Manhattan Research. He continues, "Brand teams and agencies are being challenged to demonstrate the economic and strategic value created by these online destinations - beyond the raw number of visitors or page views. After all, if a site is all traffic and no action then what is the strategic value of the site?"

Top 10 Pharmaceutical Branded Websites Driving Prescription Drug Requests

1. Chantix

2. Cialis

3. Viagra

4. Aciphex

5. Ambien CR

6. Levitra

7. Lamisil

8. Lunesta

9. Wellbutrin XL

10. Ortho Evra

Source: ePharma Consumer(R) v7.0, Manhattan Research, LLC

To learn more about consumer segments of pharmaceutical information seekers, contact Manhattan Research by visiting http://www.manhattanresearch.com/ePC.htm or by emailing sales@manhattanresearch.com.

Some of the additional product sites researched within ePharma Consumer(R) v7.0 include the following: Abilify, Actonel, Advair, Aranesp, Aricept, Avandia, Boniva, Botox, Caduet, Concerta, Crestor, Cymbalta, Depakote, Depo- Provera, Detrol LA, Effexor XR, Enbrel, Flomax, Flonase, Flovent, Fosamax, Gardasil, Glucophage XR, Humira, Humulin, Imitrex, Lantus, Lexapro, Lipitor, Nasacort, Nasonex, Neulasta, Neurontin, Nexium, Norvasc, NuvaRing, Ortho Tri- Cyclen Lo, Paxil, Plavix, Pravachol, Prevacid, Protonix, Provigil, Pulmicort, Restasis, Risperdal, Rozerem, Seasonale, Seroquel, Singulair, Strattera, Tamiflu, Topamax, Toprol XL, Tricor, Valtrex, Vytorin, Yasmin, Yaz, Zocor, Zoloft, Zomig, Zyprexa and Zyrtec.

Please visit http://www.manhattanresearch.com/ePC.htm to download the ePharma Consumer(R) product brochure, request subscription information, and to listen to two audio presentations summarizing highlights from the research.

Manhattan Research

ePharma Consumer(R) v7.0 is a syndicated multi-client study and advisory service focused on key research topics and trends impacting online U.S. consumers seeking pharmaceutical information. The study was fielded in December 2007 among 5,112 U.S. adult consumers. In addition to ePharma Consumer(R), Manhattan Research conducts five additional research studies annually among consumers and physicians in the United States and in Europe: Cybercitizen(R) Health US, Cybercitizen(R) Health Europe, Taking the Pulse(R) US, Taking the Pulse(R) Europe, and ePharma Physician(R). Each study serves a unique purpose and focuses on specific aspects of information technology adoption. Broad consumer and physician research is complemented by targeted analyses among more than 50 consumer therapeutic segments and 25 physician specialist segments.

Contact:

Erica Alexander Martini

212-255-7799

Ealexander@Manhattanresearch.Com


'/>"/>
SOURCE Manhattan Research
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Research Triangle Area Health Care Collaborative Launches Bridges to Excellence(R) Initiative to Improve Quality and Lower Costs
2. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
3. BioMarin Licenses Technology From Leading Cystic Fibrosis Research Laboratory at the University of California, San Francisco
4. IDM Pharma Names Dr. Jeffrey W. Sherman Chief Medical Officer and Senior Vice President of Research and Development
5. Dawson James Securities Initiates Research Coverage on CryoCor, Inc. (Nasdaq: CRYO) with a Strong Buy Rating and $6.00 Target Price
6. eResearchTechnology to Present at the Thomas Weisel Healthcare Conference 2007 on September 5th
7. The Debiopharm Life Sciences Award Goes to Dr Nusser for his Outstanding Research in Neuroscience
8. Study Published in Clinical Cancer Research Confirms Potential Of Peregrines Bavituximab Combined With Radiation In Lung Cancer
9. Dow AgroSciences and Exelixis Plant Sciences Announce Major Research Collaboration, Asset Purchase to Advance Gene Discovery and Validation
10. Revolutionary Genomics Research Group Opens Boston Office; Provides DNA Evidence in Workers Comp Cases
11. Richard Schulz Receives the Coveted GCPj Award for Best Clinical Researcher of the Year
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/24/2017)... ... January 24, 2017 , ... Men who have a ... had a positive association with increased prostate growth or benign prostatic hyperplasia, according ... Journal involved 571 Korean men who underwent urological examinations, including serum prostate ...
(Date:1/24/2017)... USA & Geneva, Switerland (PRWEB) , ... January ... ... to announce the first commercially available malaria Plasmodium falciparum culture panels with standard ... falciparum culture panels, which are available in a range of concentrations from six ...
(Date:1/24/2017)... LAVAL, QC , Jan. 24, 2017 /PRNewswire/ - ProMetic ... the "Corporation") announced today that its orally active lead ... Medicine ("PIM") designation by the UK Medicines and Healthcare ... Syndrome ("AS"). A PIM designation is ... promising candidate for the Early Access to Medicines Scheme ...
(Date:1/24/2017)... DC (PRWEB) , ... January 23, 2017 , ... ... and food security, is the first-ever recipient of the National Academy of Sciences ... to global food security and nutrition. , The annual National Academy of Sciences ...
Breaking Biology Technology:
(Date:12/16/2016)... -- The global wearable medical device market, in terms of value, ... 5.31 billion in 2016, at a CAGR of 18.0% during the ... ... medical devices, launch of a growing number of smartphone-based healthcare apps ... providers, and increasing focus on physical fitness. Furthermore, ...
(Date:12/15/2016)... ... has announced the addition of the "Global Military Biometrics Market 2016-2020" ... global military biometrics market to grow at a CAGR of 7.5% during ... on an in-depth market analysis with inputs from industry experts. The report ... The report also includes a discussion of the key vendors operating in ...
(Date:12/15/2016)... 14, 2016 "Increase in mobile transactions is ... mobile biometrics market is expected to grow from USD ... 2022, at a CAGR of 29.3% between 2016 and ... the growing demand for smart devices, government initiatives, and ... "Software component is expected to grow at a high ...
Breaking Biology News(10 mins):